Key indicators: single-crystal X-ray study; T = 100 K; mean (C-C) = 0.003 Å; R factor = 0.065; wR factor = 0.138; data-to-parameter ratio = 22.1.
Experimental
Crystal data Mo K radiation = 0.08 mm À1 T = 100 K 0.35 Â 0.18 Â 0.11 mm
Data collection
Bruker SMART APEXII CCD diffractometer Absorption correction: multi-scan (SADABS; Bruker, 2009 ) T min = 0.972, T max = 0.991 12642 measured reflections 3300 independent reflections 2653 reflections with I > 2(I) R int = 0.026 Refinement R[F 2 > 2(F 2 )] = 0.065 wR(F 2 ) = 0.138 S = 1.13 3300 reflections 149 parameters H atoms treated by a mixture of independent and constrained refinement Á max = 0.36 e Å À3 Á min = À0.29 e Å À3 Table 1 Hydrogen-bond geometry (Å , ).
Cg1 is the centroid of the C1-C6 phenyl ring. Symmetry codes: (i) Àx þ 1; y þ 1 2 ; Àz þ 1 2 ; (ii) Àx; y À 1 2 ; Àz þ 1 2 ; (iii) x; Ày þ 1 2 ; z À 3 2 .
Data collection: APEX2 (Bruker, 2009 ); cell refinement: SAINT (Bruker, 2009 ); data reduction: SAINT; program(s) used to solve structure: SHELXTL (Sheldrick, 2008) ; program(s) used to refine structure: SHELXTL; molecular graphics: SHELXTL; software used to prepare material for publication: SHELXTL and PLATON (Spek, 2009 
(E)-N-[3-(Imidazol-1-yl)-1-phenylpropylidene]hydroxylamine
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Ghoneim Comment
A significant increase in fungal infections has been observed over the past three decades. Many reports of invasive topical and systemic infections caused by the opportunistic pathogen Candida species are always associated with the use of broad-spectrum antibiotics, immunosuppressive agents, anticancer and anti-AIDS drugs (Weinberg, 1996) . One of the major problems in the treatment of Candida infections is the spread of antifungal drug resistance mainly in patients chronically subjected to antimycotic therapy such as HIV-infected patients (Wildfeuer et al., 1998; Georgopapadakou, 1998) . Azoles are commonly used as antifungal agent specially for Candida infections as many marketed drugs contain the azole moiety. The title compound contains the azole moiety and it was prepared to test its antifungal potential and will be further elaborated to other azole-containing new bioactive chemical entities.
In the title compound, Fig.1 , the imidazole ring (N2/N3/C10-C12, maximum deviation of 0.001 (2) Å at atoms N3, C11 and C12) forms a dihedral angle of 75.97 (10)° with the phenyl ring (C1-C6). Bond lengths (Allen et al., 1987) and angles are within normal ranges. The title compound exists in trans configuration with respect to the C7═N1 bond [1.285 (2) Å].
In the crystal structure, Fig. 2 , molecules are linked via intermolecular O1-H1O1···N3 and C2-H2A···N1 hydrogen bonds (Table 1) into two-dimensional networks parallel to (001). The crystal structure is further consolidated by C12-H12A···Cg1 iii (Table 1) interactions, where Cg1 is the centroid of C1-C6 phenyl ring.
Experimental
A mixture of 3-(1H-imidazol-1-yl)-1-phenylpropan-1-one (0.02 g, 0.1 mmol), hydroxylamine hydrochloride (0.14 g, 0.2 mol), and KOH (0.112 g, 0.2 mmol) in ethanol (10 ml) was refluxed under stirring for 18h. The reaction mixture was allowed to cool to room temperature and the insolubles were removed by filtration. The filtrate was evaporated under vacuum and the residue was suspended in water (10 ml), filtered, dried and recrystallized from ethanol to yield colourless blocks of the title compound.
Refinement
Atom H1O1 was located in a difference Fourier map and refined freely with O1-H1O1 = 0.90 (3) Å. The remaining H atoms were positioned geometrically and refined using a riding model with C-H = 0.95 or 0.99 Å and U iso (H) = 1.2 U eq (C).
Computing details
Data collection: APEX2 (Bruker, 2009 ); cell refinement: SAINT (Bruker, 2009 ); data reduction: SAINT (Bruker, 2009 ); program(s) used to solve structure: SHELXTL (Sheldrick, 2008) ; program(s) used to refine structure: SHELXTL (Sheldrick, 2008) ; molecular graphics: SHELXTL (Sheldrick, 2008) ; software used to prepare material for publication: SHELXTL (Sheldrick, 2008) and PLATON (Spek, 2009 ).
Figure 1
The molecular structure of the title compound showing 50% probability displacement ellipsoids for non-H atoms. (Cosier & Glazer, 1986) operating at 100.0 (1) K. Geometry. All esds (except the esd in the dihedral angle between two l.s. planes) are estimated using the full covariance matrix. The cell esds are taken into account individually in the estimation of esds in distances, angles and torsion angles; correlations between esds in cell parameters are only used when they are defined by crystal symmetry. An approximate (isotropic) treatment of cell esds is used for estimating esds involving l.s. planes. Refinement. Refinement of F 2 against ALL reflections. The weighted R-factor wR and goodness of fit S are based on F 2 , conventional R-factors R are based on F, with F set to zero for negative F 2 . The threshold expression of F 2 > 2sigma(F 2 ) is used only for calculating R-factors(gt) etc. and is not relevant to the choice of reflections for refinement. R-factors based on F 2 are statistically about twice as large as those based on F, and R-factors based on ALL data will be even larger.
Fractional atomic coordinates and isotropic or equivalent isotropic displacement parameters (Å 2 ) (7) 0.0180 (7) 0.0258 (7) −0.0076 (6) 0.0066 (6) −0.0048 (6) N1 0.0181 (8) 0.0159 (7) 0.0232 (8) −0.0006 (6) 0.0033 (6) −0.0019 (6) N2 0.0154 (7) 0.0140 (7) 0.0169 (7) 0.0004 (6) 0.0004 (6) −0.0012 (6) N3 0.0239 (9) 0.0225 (9) 0.0261 (9) 0.0041 (7) 0.0016 (7) 0.0042 (7) C1 0.0178 (9) 0.0193 (9) 0.0181 (8) −0.0008 (7) −0.0018 (7) −0.0015 (7) C2 0.0223 (9) 0.0185 (9) 0.0221 (9) −0.0049 (7) −0.0049 (7) 0.0010 (7) C3 0.0201 (9) 0.0263 (10) 0.0204 (9) −0.0036 (8) 0.0003 (7) 0.0064 (8) C4 0.0199 (9) 0.0263 (10) 0.0185 (9) 0.0017 (8) 0.0023 (7) 0.0015 (7) C5 0.0195 (9) 0.0184 (9) 0.0205 (9) 0.0012 (7) −0.0001 (7) −0.0014 (7) (7) −0.0021 (7) 0.0029 (6) C9 0.0205 (9) 0.0148 (8) 0.0179 (8) 0.0014 (7) 0.0030 (7) 0.0021 (7) C10 0.0207 (9) 0.0190 (9) 0.0191 (9) 0.0026 (7) −0.0017 (7) −0.0009 (7) 
